Did Stoke's New R&D Chair Appointment Just Reshape Stoke Therapeutics' (STOK) Antisense Strategy Priorities?

Simply Wall St.

Apr 16

Earlier in April 2026, Stoke Therapeutics expanded its Board of Directors to ten members and appointed G. Clare Kahn, Ph.D., a veteran of Pfizer, GlaxoSmithKline and X-VAX, as a Class I director and ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2627266560"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2627266560\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2627266560?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","is_english":true,"pubTime":"2026-04-16 13:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2627266560","market":"nz","top_or_hot":-1,"title":"Did Stoke's New R&D Chair Appointment Just Reshape Stoke Therapeutics' (STOK) Antisense Strategy Priorities?","media":"Simply Wall St.","content":"<div>\n<p>Earlier in April 2026, Stoke Therapeutics expanded its Board of Directors to ten members and appointed G. Clare Kahn, Ph.D., a veteran of Pfizer, GlaxoSmithKline and X-VAX, as a Class I director and ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-stok/stoke-therapeutics/news/did-stokes-new-rd-chair-appointment-just-reshape-stoke-thera\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Did Stoke's New R&D Chair Appointment Just Reshape Stoke Therapeutics' (STOK) Antisense Strategy Priorities?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDid Stoke's New R&D Chair Appointment Just Reshape Stoke Therapeutics' (STOK) Antisense Strategy Priorities?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-04-16 13:04 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-stok/stoke-therapeutics/news/did-stokes-new-rd-chair-appointment-just-reshape-stoke-thera><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Earlier in April 2026, Stoke Therapeutics expanded its Board of Directors to ten members and appointed G. Clare Kahn, Ph.D., a veteran of Pfizer, GlaxoSmithKline and X-VAX, as a Class I director and ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-stok/stoke-therapeutics/news/did-stokes-new-rd-chair-appointment-just-reshape-stoke-thera\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"STOK","symbol_name":"Stoke Therapeutics, Inc.","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-stok/stoke-therapeutics/news/did-stokes-new-rd-chair-appointment-just-reshape-stoke-thera","article_id":"2627266560","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-stok/stoke-therapeutics/news/did-stokes-new-rd-chair-appointment-just-reshape-stoke-thera","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2627266560","pubTimestamp":1776315861,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Earlier in April 2026, Stoke Therapeutics expanded its Board of Directors to ten members and appointed G. Clare Kahn, Ph.D., a veteran of Pfizer, GlaxoSmithKline and X-VAX, as a Class I director and chair of the Board’s Research and Development Committee.\nHer combination of deep regulatory, preclinical and lifecycle management experience could meaningfully influence how Stoke prioritizes and advances its antisense pipeline for severe genetic diseases.\nNext, we’ll consider how Dr. Kahn’s...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"STOK":"Stoke Therapeutics, Inc.","BK4139":"生物科技"},"translate_title":"Stoke的新研发主席任命是否重塑了Stoke Therapeutics(STOK)的反义战略重点？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"STOK":1.5},"content_text":"Earlier in April 2026, Stoke Therapeutics expanded its Board of Directors to ten members and appointed G. Clare Kahn, Ph.D., a veteran of Pfizer, GlaxoSmithKline and X-VAX, as a Class I director and chair of the Board’s Research and Development Committee. Her combination of deep regulatory, preclinical and lifecycle management experience could meaningfully influence how Stoke prioritizes and advances its antisense pipeline for severe genetic diseases. Next, we’ll consider how Dr. Kahn’s appointment, particularly her leadership of the Research and Development Committee, may shape Stoke’s investment narrative. Find 60 companies with promising cash flow potential yet trading below their fair value.AdvertisementStoke Therapeutics Investment Narrative RecapTo own Stoke Therapeutics, you have to believe that zorevunersen can clear late stage regulatory hurdles in Dravet syndrome and that the antisense platform can extend into other severe genetic diseases like Autosomal Dominant Optic Atrophy. The near term catalyst is progress and clarity around the Phase III EMPEROR program and its regulatory path, while the biggest risk remains that pivotal data or regulators do not align with earlier, smaller studies. Dr. Kahn’s appointment does not materially change those near term scientific and regulatory risks, but it could influence how they are managed. The most relevant recent announcement here is Stoke’s January 2026 update confirming EMPEROR enrollment targeting completion in Q2 2026, with a Phase III data readout expected in mid 2027 and a rolling NDA submission planned for the first half of 2027 under Breakthrough Therapy designation. Against that backdrop, adding a director with deep regulatory and lifecycle management expertise to chair the R&D Committee sits squarely in the context of preparing for those critical interactions and potential submission milestones. Yet alongside this progress, investors should be aware that long term safety findings in Dravet and ADOA, including CSF protein elevations and other adverse events, could... Read the full narrative on Stoke Therapeutics (it's free!)Stoke Therapeutics' narrative projects $81.1 million in revenue and $13.2 million in earnings by 2028. This implies revenue declining by 26.7% per year and an earnings decrease of $27.4 million from $40.6 million today.Uncover how Stoke Therapeutics' forecasts yield a $34.25 fair value, a 4% downside to its current price.Exploring Other PerspectivesSTOK 1-Year Stock Price Chart The highest analyst estimates were already assuming about US$63,400,000 of revenue and US$10,200,000 of earnings by 2028, so this new R&D leadership may either reinforce that optimistic view of Stoke’s ability to execute on EMPEROR and ADOA or cause some to rethink it, especially if you worry that concentration in rare, high priced indications could become a bigger constraint than the consensus narrative suggests.Explore 4 other fair value estimates on Stoke Therapeutics - why the stock might be worth over 8x more than the current price!Decide For YourselfDisagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.A great starting point for your Stoke Therapeutics research is our analysis highlighting 3 key rewards and 2 important warning signs that could impact your investment decision.Our free Stoke Therapeutics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Stoke Therapeutics' overall financial health at a glance.Curious About Other Options?Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:We've uncovered the 11 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.Capitalize on the AI infrastructure supercycle with our selection of the 37 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.Explore 25 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"executive","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}